What is HC Wainwright’s Estimate for Pharvaris Q4 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Analysts at HC Wainwright issued their Q4 2027 earnings per share estimates for Pharvaris in a note issued to investors on Friday, August 14th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.65) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Pharvaris’ FY2030 earnings at $6.60 EPS.

Other research analysts also recently issued research reports about the company. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Thursday. Wells Fargo & Company began coverage on shares of Pharvaris in a report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target for the company. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Guggenheim lifted their price objective on shares of Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.08.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $35.32 on Monday. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.58 and a beta of -2.31. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $36.93. The stock has a fifty day moving average price of $33.79 and a 200-day moving average price of $30.17.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06).

Institutional Investors Weigh In On Pharvaris

A number of hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Pharvaris during the 2nd quarter valued at approximately $196,000. Seven Fleet Capital Management LP acquired a new stake in Pharvaris in the second quarter valued at approximately $26,782,245,000. Bank of America Corp DE acquired a new stake in Pharvaris in the second quarter valued at approximately $4,800,000. Elmind Capital LP bought a new stake in shares of Pharvaris during the second quarter worth $18,180,435,000. Finally, 5AM Venture Management LLC acquired a new position in shares of Pharvaris during the second quarter worth $27,581,008,000.

Insider Buying and Selling at Pharvaris

In related news, insider Anne Lesage sold 27,872 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total value of $988,898.56. Following the sale, the insider directly owned 58,750 shares of the company’s stock, valued at $2,084,450. This trade represents a 32.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the transaction, the insider owned 46,275 shares in the company, valued at approximately $1,428,509.25. This represents a 5.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 156,030 shares of company stock worth $5,304,914 over the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.